SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Distribution of Sales Revenues from Pharmaceutical Innovation
16 references·0 citing·40 second hop
The Distribution of Sales Revenues from Pharmaceutical Innovation (2000)The Distribution of Sales Revenues from P…Uncertainty and the size distribution of rewards from innovation (2001)Uncertainty and the size dist…The determinants of pharmaceutical research and development expenditures (2001)The determinants of pharmaceu…Uncertainty and the size distribution of rewards from innovation (2000)Uncertainty and the size dist…The determinants of pharmaceutical research and development expenditures (2000)The determinants of pharmaceu…Effective patent life in pharmaceuticals (2000)Effective patent life in phar…New perspectives on economic growth and technological innovation (1999)New perspectives on economic …The Economics of New Goods (1997)The Economics of New GoodsPharmacy benefit management, cost-effectiveness analysis and drug formulary decisions (1997)Pharmacy benefit management, …Longer Patents for Increased Generic Competition in the US (1996)Longer Patents for Increased …Competitive Strategies in the Pharmaceutical Industry (1996)Competitive Strategies in the…Success rates for new drugs entering clinical testing in the United States (1995)Success rates for new drugs e…Returns to R&D on new drug introductions in the 1980s (1994)Returns to R&D on new drug in…Innovation and Structural Change in Pharmaceuticals and Biotechnology (1994)Innovation and Structural Cha…Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…The structure and governance of venture-capital organizations (1990)The structure and governance …A New Look at the Returns and Risks to Pharmaceutical R&D (1990)A New Look at the Returns and…Job Market Signaling (1973)Theory of the firm: Managerial behavior, agency costs and ownership structure (1976)Agency Costs of Free Cash Flow, Corporate Finance, and Takeovers (1986)The Modern Industrial Revolution, Exit, and the Failure of Internal Control Systems (1993)The economics of small business finance: The roles of private equity and debt markets in the financial growth cycle (1998)A Review of IPO Activity, Pricing, and Allocations (2002)Invention and Economic Growth (1966)Industrial Market Structure and Economic Performance. (1971)Measuring Competence? Exploring Firm Effects in Pharmaceutical Research (1994)‘Inequality’ of innovation: skewed distributions and the returns to innovation in Dutch manufacturing (2004)The Market Valuation of Knowledge Assets in US and European Firms (2006)The innovation debt penalty: Cost of debt, loan default, and the effects of a public loan guarantee on high-tech firms (2017)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Cutting the cost of drug development? (2004)Generic competition and market exclusivity periods in pharmaceuticals (2007)The Pharmaceutical Industry (2013)On the Misuse of Accounting Rates of Return to Infer Monopoly Profits (2016)Composition of R and D Expenditures: Relationship to Size of Firm, Concentration, and Innovative Output (1981)The pharmaceutical industry as a medicines provider (2002)Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry (2005)Performance effects of imitative entry (2008)Market Structure and Technological Change (2013)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)The cost of biopharmaceutical R&D: is biotech different? (2007)Essential medicines for universal health coverage (2016)The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001 (2003)The Cambridge Economic History of Modern Britain (2004)Estimating Market Power and Strategies (2007)Price Competition in Pharmaceuticals: The Case of Anti‐infectives (2004)Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (2016)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Innovative productivity and returns to scale in the pharmaceutical industry (1993)Pricing, Profits, and Technological Progress in the Pharmaceutical Industry (1993)Who's the new kid? The process of developing centrality in venture capitalist deal networks (2008)Does the Riskiness of R&D Outweigh Its Benefits? The Perspective of US Private Lenders (2016)The Economics of Innovation, New Technologies and Structural Change (2010)The Oxford Handbook of the Italian Economy Since Unification (2013)Challenging the “deficit model” of innovation: Framing policy issues under the innovation imperative (2018)
this work references cited by second hop

References

  • 1990The structure and governance of venture-capital organizations2,609 cited
  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 1997The Economics of New Goods297 cited
  • 1990A New Look at the Returns and Risks to Pharmaceutical R&D286 cited
  • 1999New perspectives on economic growth and technological innovation205 cited
  • 1994Returns to R&D on new drug introductions in the 1980s197 cited
  • 1995Success rates for new drugs entering clinical testing in the United States184 cited
  • 2000Uncertainty and the size distribution of rewards from innovation143 cited
  • 1996Longer Patents for Increased Generic Competition in the US136 cited
  • 2001Uncertainty and the size distribution of rewards from innovation116 cited
  • 2000The determinants of pharmaceutical research and development expenditures109 cited
  • 2001The determinants of pharmaceutical research and development expenditures97 cited
  • 1997Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions94 cited
  • 1996Competitive Strategies in the Pharmaceutical Industry93 cited
  • 2000Effective patent life in pharmaceuticals91 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 1994Innovation and Structural Change in Pharmaceuticals and Biotechnology80 cited
  • Cited by

    No citing works inside the corpus for this window.